Period:
Draw Mode:
| Volume | 40,396 |
|
|||||
| News | - | ||||||
| Day High | 4.25 | Low High |
|||||
| Day Low | 3.9218 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Evelo Biosciences Inc | EVLO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 4.00 | 15:44:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.06 | 3.9218 | 4.25 | 4.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 358 | 40,396 | $ 4.04 | $ 163,310 | - | 1.586 - 48.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:46:38 | 1 | $ 3.99 | USD |
Evelo Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 75.34M | 18.84M | - | 0 | -114.53M | -6.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Evelo Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EVLO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.33 | 4.43 | 3.57 | 4.00 | 113,220 | -0.33 | -7.62% |
| 1 Month | 6.63 | 7.6892 | 3.57 | 5.36 | 113,589 | -2.63 | -39.67% |
| 3 Months | 2.57 | 13.93 | 2.31 | 7.90 | 612,175 | 1.43 | 55.64% |
| 6 Months | 4.34 | 13.93 | 1.586 | 3.52 | 5,663,280 | -0.34 | -7.83% |
| 1 Year | 39.40 | 48.40 | 1.586 | 4.01 | 2,909,196 | -35.40 | -89.85% |
| 3 Years | 102.00 | 398.566 | 1.586 | 26.95 | 1,153,048 | -98.00 | -96.08% |
| 5 Years | 245.20 | 398.566 | 1.586 | 31.00 | 720,711 | -241.20 | -98.37% |
Evelo Biosciences Description
| Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer. |